JBiSE  Vol.5 No.3 , March 2012
Polymixin-B hemoperfusion in a case intolerant to conventional antibiotic therapy
ABSTRACT
In this study we document how it was possible to resolve the septic complications of abdominal surgery, subjecting a patient severely allergic to intravenous antibiotics. We performed the hemoperfusion with polymyxin-B columns (PMX-DHP), guiding the therapy by assaying endotoxin activity and evaluating the clinical status of the patient after each session of PMX-DHP. The stabilization of hemodynamic and inflammatory frameworks were immediately observed after the PMX-DHP. The patient could be safely discharged five days after the discontinuation of the therapy. Our findings confirms data already published in literature concerning the effectiveness of PMX-DHP.

Cite this paper
Novelli, G. , Morabito, V. , Ferretti, G. , Novelli, S. , Ruberto, F. , Pernice, M. , Cristina Donfrancesco, C. and Panici, P. (2012) Polymixin-B hemoperfusion in a case intolerant to conventional antibiotic therapy. Journal of Biomedical Science and Engineering, 5, 101-103. doi: 10.4236/jbise.2012.53013.
References
[1]   Tani, T., Shoji, H., Guadagni, G. and Perego, A. (2010) Extracorporeal removal of endotoxin: The polymyxin B-immobilized fiber cartridge. Contributions to Nephrology, 167, 35-44. doi:10.1159/000315917

[2]   Cruz, D.N., Perazella, M.A., Bellomo, R., et al. (2007) Effectiveness of polymyxin B-immobilized fiber column in sepsis: A systematic review. Critical Care, 11, R47. doi:10.1186/cc5780

[3]   Cantaluppi, V., Assenzio, B., Pasero, D., et al. (2008) Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Medicine, 34, 1638-1645. doi:10.1007/s00134-008-1124-6

[4]   Shoji, H. (2003) Extracorporeal endotoxin removal for the treatment of sepsis: Endotoxin adsorption cartridge (Toraymyxin). Therapeutic Apheresis and Dialysis, 7, 108-114. doi:10.1046/j.1526-0968.2003.00005.x

[5]   Shimizu, T., Yoshihiro, E., Tsuchihashi, H., et al. (2006) Endotoxin apheresis for sepsis. Transfusion and Apheresis Science, 35, 271-282. doi:10.1016/j.transci.2006.06.006

[6]   Marshall, J.C., Foster, D., Vincent, J.L., et al. (2004) Diagnostic and prognostic implications of endotoxemia in critical illness: Results of the MEDIC study. Journal of Infectious Diseases, 190, 527-534. doi:10.1086/422254

[7]   Monti, G., Bottiroli, M., Pizzilli, G., et al. (2010) Endotoxin activity level and septic shock: A possible role for specific anti-endotoxin therapy? Contributions to Nephrology, 167, 102-110. doi:10.1159/000315924

[8]   Novelli, G., Ferretti, G., Ruberto, F., et al. (2010) Early management of endotoxemia using the endotoxin activity assay and polymyxin B-based hemoperfusion. Contributions to Nephrology, 167, 91-101. doi:10.1159/000315923

[9]   Romaschin, A.D., Harris, D.M., Ribeiro, M.B., et al. (1998) A rapid assay of endotoxin in whole blood using autologous neutrophil-dependent chemiluminescence. Journal of Immunological Methods, 212, 16-85. doi:10.1016/S0022-1759(98)00003-9

[10]   Hanasawa, K., Tani, T. and Kodama, M. (1989) New approach to endotoxic and septic shock by means of polymyxin B immobilized fiber. Surgery Gynecology & Obstetrics, 168, 323-331.

[11]   Shoji, H., Tani, T., Hanasawa, K. and Kodama, M. (1998) Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: Designing and antiendotoxin efficacy in the clinical application. Therapeutic Apheresis, 2, 3-12. doi:10.1111/j.1744-9987.1998.tb00066.x

 
 
Top